Innovent Announces NMPA Approval of TYVYT® (Sintilimab) Plus ELUNATE® (Fruquintinib) for Advanced Renal Cell Carcinoma in China 1
Innovent Biologics: NMPA Approval for Sintilimab + Fruquinti...
Sign in to continue:
Innovent Biologics: NMPA Approval for Sintilimab + Fruquinti...
China International Development Corporation Limited Announce...
Sunshine Lake Pharma Co., Ltd. Completes H Share Full Circul...
China Metal Resources Utilization Limited Announces Delay in...
Shenzhen International Holdings Limited Announces Scrip Divi...
Shenzhen International Holdings: 2025 Final Dividend & Scrip...
VTech Holdings FY2026 Annual Results: In-Depth Investor Anal...
Key Highlights Yidu Tech Inc. (Stock Code: 2158) has an...
Deepexi Technology Announces HK\$401.7 Million Placing of Ne...
Jenscare Scientific Co., Ltd. Announces Positive 12-Month Cl...